Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AstraZeneca PLC to Cut Jobs as Part of Restructuring
AstraZeneca PLC announced a restructuring of its SG&A activities that will result in a global reduction in headcount of approximately 2,300. The majority of this headcount impact is related to programs under way or already communicated to affected employees. The Company is combining this SG&A restructuring with two previously announced programs. These comprise the headcount reduction of 1,600 related to the proposed Research & Development footprint changes announced on March 18, 2013, and the balance of the Phase 3 restructuring program announced in February 2012, which amounts to 1,150 roles. The total combined Phase 4 program entails an estimated global headcount reduction of approximately 5,050 over the period between 2013 and 2016.
Latest Developments for AstraZeneca PLC
- AstraZeneca PLC Reaffirms FY 2013 Guidance-Conference Call
- AstraZeneca PLC Announces Top-Line Results From OSKIRA-1 Phase 3 Study Of Fostamatinib In Rheumatoid Arthritis
- AstraZeneca PLC Buys Early-Stage U.S. Biotech Firm-Reuters
- US District Court Rules AstraZeneca PLC's One Pulmicort Respules Patent Invalid
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters